Survival Rate and Prognosis for Neuroblastoma
Neuroblastoma is a rare childhood cancer that develops from immature nerve cells (neuroblasts) of the sympathetic nervous system, most often in the adrenal glands or along the spine. Understanding the neuroblastoma survival rate and prognosis is crucial for families navigating this diagnosis, since outcomes depend heavily on your child’s specific risk group rather than a single number.
Key Takeaways
- A single combined survival percentage can be misleading — your child’s outlook depends far more on their neuroblastoma risk group (low, intermediate, or high) than on one overall average.
- According to the National Cancer Institute, children with low-risk or intermediate-risk neuroblastoma have 5-year survival rates above 95%, while long-term survival for high-risk disease is below 50%, even with intensive treatment.
- Risk group is determined by a combination of your child’s age at diagnosis, the stage of disease, tumor biology (including whether the MYCN gene is amplified), and how the tumor cells look under a microscope.
- In a small number of infants — especially those with stage 4S disease — tumors can shrink or disappear on their own without chemotherapy, a documented pattern called spontaneous regression that occurs only in carefully selected, closely monitored low-risk cases.
- Anti-GD2 antibody immunotherapy, added to surgery, chemotherapy, and stem cell transplant, is now a standard part of care for high-risk neuroblastoma and has measurably improved survival for these children.
Understanding Neuroblastoma Survival Rates
When you first hear a neuroblastoma diagnosis, one of the earliest questions is almost always about survival. These figures reflect how children with neuroblastoma fared after treatment in years past; they are not a personal forecast, since your child’s actual outlook depends heavily on their specific risk group and how their tumor responds to treatment.
General Statistics and Trends
Survival for children with neuroblastoma has improved substantially over the past several decades. Between 1975 and 2020, five-year survival climbed from 86% to 93% among infants diagnosed before their first birthday, and children diagnosed between ages 1 and 14 saw their five-year survival climb from 34% up to 83% over that same stretch. More recent data, for children diagnosed between 2014 and 2020, put the combined 5-year survival rate near 85% for children younger than 15. The National Cancer Institute cautions that a figure like this can be misleading on its own: because outcomes differ so much by age, stage, and tumor biology, the risk-group breakdown described later on this page is a far more useful guide for an individual child than the overall average.
Defining Survival Rates
Survival rates are usually reported as a “5-year survival rate” — the percentage of children who are alive five years after diagnosis. Being alive at five years doesn’t always mean being cured, though many children who reach that point go on to live long, healthy lives. These numbers come from large groups of children treated in the past and don’t predict what will happen for your child; your care team is best placed to explain what the statistics mean for your child’s specific diagnosis.
Neuroblastoma Survival Rate by Stage
How far neuroblastoma has spread at diagnosis is one of several pieces doctors use to sort a child into a risk group, which in turn guides both treatment and expected outcomes.
Prognosis for Localized Disease (Stages 1, 2, 4S)
Stages 1 and 2 mean the tumor is confined to where it started or has spread only to nearby lymph nodes. These tumors, along with most stage 4S disease, generally fall into the low-risk or intermediate-risk groups, where 5-year survival rates exceed 95%. Stage 4S — sometimes called “special” neuroblastoma — affects infants younger than 12 months, where the cancer involves the skin, liver, or a limited amount of bone marrow without reaching the bones themselves; in the Children’s Oncology Group’s ANBL00B1 registry study, newly diagnosed patients with this pattern of disease had a 5-year overall survival rate of 92%. Despite the spread, many infants with favorable tumor biology do very well, and in some, the tumor shrinks or disappears on its own without chemotherapy — a pattern NCI documents as spontaneous regression. This doesn’t happen for every infant with stage 4S disease; doctors decide who is a candidate for close observation instead of treatment based on the tumor’s genetics and how the infant is doing clinically.
Prognosis for Advanced Disease (Stages 3, 4)
Stage 3 means the tumor has grown across the body’s midline or involves extensive nearby lymph nodes; stage 4 means the disease has already reached far-away parts of the body, most often bone, bone marrow, or other organs beyond the original tumor site. Children with these stages are usually, though not always, classified as high-risk, particularly when MYCN amplification or other unfavorable biology is present; some infants with stage 4 disease diagnosed before 18 months of age, when the tumor does not carry MYCN amplification, are classified as intermediate-risk instead and tend to do better than older children or infants whose tumors are MYCN-amplified. National Cancer Institute data show that long-term survival for the high-risk group overall is below 50%, even with intensive, multi-modal treatment — doctors describe it as harder to cure rather than incurable, and outcomes for this group have improved substantially over the past two decades as newer therapies, including immunotherapy, have been added to standard treatment.
Key Factors Influencing Neuroblastoma Prognosis
Beyond stage, several biological and clinical factors help doctors classify a child’s neuroblastoma into a risk group and tailor treatment.
Age, Tumor Biology, and Location
- Age at diagnosis: Children diagnosed before 18 months of age tend to have more favorable tumor biology and better outcomes overall, even when the disease has spread.
- MYCN amplification: Extra copies of the MYCN gene are one of the strongest predictors of a more aggressive tumor and are a core factor doctors use when assigning high-risk status.
- Ploidy: Tumors with hyperdiploid cells (extra chromosomes) generally behave less aggressively than diploid or near-tetraploid tumors, which are more common in high-risk disease.
- 11q deletion: Loss of part of chromosome 11q is linked to a less favorable outcome, separate from MYCN status.
- Histology: How tumor cells appear under a microscope — classified as favorable or unfavorable — adds further prognostic detail using standardized pathology criteria.
- Tumor location: Tumors starting in the chest are less often MYCN-amplified and tend to have somewhat better outcomes than those starting in the adrenal glands, though location is intertwined with these other biological factors rather than a stand-alone predictor.
Response to Initial Treatment
How well a tumor responds to the first round of chemotherapy is itself a prognostic signal. A strong response — significant shrinkage and clearing of cancer cells from the bone marrow — is a positive sign, while a tumor that responds poorly or keeps growing usually points to more aggressive disease. Detecting minimal residual disease (small amounts of remaining cancer cells found only with sensitive lab tests) after initial treatment is linked to a higher chance of relapse and guides decisions about intensifying therapy, such as adding stem cell transplantation.
Treatment Success and Long-Term Outlook
The path through neuroblastoma treatment is often long, but pediatric oncology has made real gains in outcomes. The goal extends beyond survival itself to a good quality of life afterward.
Advances in Pediatric Oncology
Modern treatment typically combines surgery, chemotherapy, radiation therapy, and — for higher-risk disease — high-dose chemotherapy with stem cell rescue. Dinutuximab, a monoclonal antibody that targets the GD2 protein on neuroblastoma cells, has become a standard part of therapy for high-risk and relapsed disease and is credited with improving survival for these children. Treatment is tailored to risk group, and clinical trials continue to test new combinations, including additional targeted drugs for tumors with specific genetic changes such as ALK alterations.
Life After Neuroblastoma
Children who finish treatment move into survivorship care, with regular follow-up to watch for recurrence. Late effects can include hearing loss, slowed tooth or bone growth, metabolic changes such as higher blood pressure or cholesterol, changes in mood or learning, and — for a small number of survivors — a second cancer, such as thyroid cancer, kidney cancer, or leukemia, occurring years later. Survivorship clinics monitor for these issues over time and can offer interventions when needed. Emotional and psychological support for the whole family, alongside ongoing medical follow-up, plays an important role in helping a child thrive after treatment ends.
Frequently Asked Questions
What is the survival rate of neuroblastoma?
It depends far more on a child’s risk group than on any single number. According to National Cancer Institute data, children with low-risk or intermediate-risk neuroblastoma have 5-year survival rates above 95%, while long-term survival for high-risk disease is below 50%, though outcomes for this group have improved substantially over the past two decades.
What is the prognosis for neuroblastoma in children?
Prognosis depends on a combination of a child’s age, disease stage, and tumor biology, including whether the MYCN gene is amplified. Younger children with localized, favorable-biology tumors generally have an excellent outlook, while older children with widespread, high-risk disease face a more guarded prognosis, though newer treatments continue to improve outcomes even in this group.
How have neuroblastoma treatment success rates improved over time?
Survival has climbed steadily as treatment has combined surgery, chemotherapy, radiation, and stem cell transplant with newer approaches. The addition of anti-GD2 antibody immunotherapy, in particular, has measurably boosted survival for children with high-risk disease, and ongoing research into targeted drugs continues to refine outcomes further.
Sources
